Mr. Sungju Kim is an expert advisor for Lee & Ko's Healthcare Practice Group. Prior to joining Lee & Ko, Mr. Kim acquired extensive experience in various areas relating to pharmaceutical products while working for more than 10 years at major pharmaceutical companies (Novartis and Sanofi), where his work included conducting analyses concerning new drug pricing and life-cycle management. He is also credited for carrying out influential price analysis work relating specifically to pharmaceutical products in the broader sphere of the OECD (Organization for Economic Co-operation and Development) countries, as well as conducting a significant price analysis study on the current state of access to new drugs in Korea under the Positive List System (PLS).

Mr. Kim's experience also includes serving as a medical statistician at the Medical Research Collaborating Center of the Seoul National University Hospital, as well as doing clinical statistics and data analysis work for the KCDC (Korea Centers for Disease Control & Prevention).

Drawing upon his extensive experience and special expertise in the areas mentioned above, Mr. Kim produces valuable economic assessments and big data analytics relevant to pharmaceutical product pricing issues for various types of clients, including pharmaceutical bio companies, medical institutions and research institutes.